On June 23, 2025, Sana Biotechnology shared six-month results from its first in-human clinical trial with its genetically modified therapy, UP421.
These insulin-producing islet cells are hypoimmune — enabling them to produce insulin successfully in people with type 1 diabetes without immunosuppression therapy.
C-peptide levels, a marker of insulin production, remained detectable after six months. C-peptide levels also spiked during meals, demonstrating a true insulin response to rising blood sugar levels.
Learn more here: https://youtu.be/wUfX0w4pHuU
Ginger Vieira has lived with type 1 diabetes since 1999 along with a few other chronic illnesses! She is the Cofounder of the Diabetes Nerd Network and the Diabetes Nerd Marketing agency. Ginger has authored hundreds of articles and several books, including Exercise with Type 1 Diabetes, Pregnancy with Type 1 Diabetes, Dealing with Diabetes Burnout, and Stop Overeating During Lows. Over her 20-year career (so far) in diabetes, she’s produced hundreds of articles and videos about life with diabetes. Her background includes a Bachelor of Science in professional writing and certifications in coaching, personal training, powerlifting, and Ashtanga yoga.